Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax, Inc. (NASDAQ: NVAX) reported significant progress in Q1 2021, achieving 96.4% efficacy against the original COVID-19 strain and 86.3% against the B.1.1.7 variant in a Phase 3 UK trial. The company reported revenues of $447 million compared to $3 million in Q1 2020, but incurred a net loss of $223 million per share, up from $26 million a year earlier. Novavax also bolstered its manufacturing capacity with plans to produce 100 million doses per month by Q3 2021 and secured several global agreements for vaccine distribution.
Novavax (Nasdaq: NVAX) announced promising results from a preclinical study of its combination vaccine, NanoFlu/NVX-CoV2373, which targets both influenza and COVID-19. The vaccine demonstrated strong immune responses against influenza A, B, and SARS-CoV-2, with clinical trials expected to start by year-end. The study showed that the combination vaccine elicited comparable antibody responses to individual vaccines and effectively protected hamsters from SARS-CoV-2 infection. Novavax aims to address public health needs with this novel vaccine strategy.
Novavax has finalized an advance purchase agreement (APA) with Gavi to supply 350 million doses of its COVID-19 vaccine, NVX-CoV2373, to the COVAX Facility starting Q3 2021. In total, 1.1 billion doses will be distributed, with the Serum Institute of India handling the remainder. The APA, supported by CEPI's investment of nearly $400 million, aims to enhance equitable vaccine access. Novavax's CEO emphasized the importance of collaboration for global health, while Gavi highlighted the deal as a major step towards delivering 2 billion doses in 2021.
Novavax, Inc. (Nasdaq: NVAX) announced the publication of initial results from a Phase 2b clinical trial of its NVX-CoV2373 COVID-19 vaccine in South Africa, appearing in the New England Journal of Medicine. The vaccine achieved an overall efficacy of 49%, with 60% efficacy among healthy adults without HIV. Despite the presence of the B.1.351 variant, severe cases occurred only in the placebo group. The data suggest the need for ongoing evaluation against variants. The trial emphasizes the vaccine's safety and supports its ongoing development for pandemic response.
Novavax, Inc. (Nasdaq: NVAX) has initiated a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, a COVID-19 vaccine candidate. The PREVENT-19 trial will now evaluate up to 3,000 adolescents aged 12-17 across 75 U.S. sites. Participants will receive either the vaccine or placebo in two doses. The study aims to further assess safety and efficacy data established in adults. Results thus far indicate robust immune responses, positioning Novavax as a key player in the global vaccination effort against COVID-19.
Novavax, Inc. (Nasdaq: NVAX) will report its Q1 2021 financial results and operational highlights on May 10, 2021, after U.S. market close. A conference call will occur at 4:30 p.m. ET, with dial-in options available for domestic and international participants. Details for the call, including replay options starting May 10 at 7:30 p.m. ET, are provided in the press release. Novavax is advancing its COVID-19 vaccine candidate and its quadrivalent influenza vaccine towards regulatory submission, utilizing its proprietary technology to address global health needs.
Novavax, Inc. (Nasdaq: NVAX) announced a Phase 2b clinical trial revealing a 77% efficacy rate for its malaria vaccine candidate, R21, developed with the University of Oxford. This study, published in Preprints with The Lancet, involved 450 children in Burkina Faso and highlighted the well-tolerated nature of the vaccine. The Royalty agreement with the Serum Institute of India allows for the production of at least 200 million doses annually. A Phase 3 trial is now recruiting participants across Africa to assess the vaccine's safety and efficacy on a larger scale.
Novavax, Inc. (Nasdaq: NVAX) announced its participation in the Phase 2 Com-COV2 clinical trial led by the University of Oxford, evaluating the efficacy of mixed COVID-19 vaccine regimens. The trial includes 1,050 adults over 50, assessing responses to NVX-CoV2373 alongside other vaccines. The study aims to determine if combining different vaccines can safely enhance immune responses compared to standard regimens. NVX-CoV2373 has shown strong efficacy in previous trials and is designed for stable storage and distribution.
On April 13, 2021, Novavax, Inc. (Nasdaq: NVAX) announced significant leadership changes, promoting Gale E. Smith to Senior VP of Discovery and Pre-Clinical Research, and appointing Troy Morgan as Senior VP and Chief Compliance Officer. Greg Covino will step down as CFO but remain as an executive adviser. Dr. Smith is recognized for his contributions to vaccine technology, while Mr. Morgan brings extensive compliance expertise. These changes come as Novavax progresses in the commercialization of its COVID-19 vaccine and seeks to enhance its operational compliance.
On April 13, 2021, Novavax, Inc. (Nasdaq: NVAX) announced key leadership changes, promoting Gale E. Smith, Ph.D., to Senior VP and Chief Scientist, while appointing Troy Morgan as Senior VP and Chief Compliance Officer. Greg Covino will step down as CFO but remain as an executive adviser. Dr. Smith's contributions to Novavax's COVID-19 vaccine candidate and vaccine technology development were highlighted. Morgan brings extensive compliance experience, crucial for Novavax's commercialization strategy. These changes reflect the company's commitment to advancing vaccine solutions against serious infectious diseases.